← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Astraea Therapeutics, Llc
Mountain View, CA
$26,246,039
Total funding
14
Grants
Funding over time
peak $3.6M · FY2009–24$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$26,246,039 · 14
By mechanism
U01$9,559,916 · 2
R01$4,377,025 · 2
UH3$4,073,436 · 1
R44$3,001,027 · 2
UG3$2,916,188 · 1
N44$999,993 · 1
Investigators at Astraea Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$2,183,507
UH3 · FY2023 · DA
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$2,158,836
U01 · FY2019 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,107,278
U01 · FY2022 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$2,007,282
U01 · FY2021 · DA
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,458,094
UG3 · FY2020 · DA
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,458,094
UG3 · FY2019 · DA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence$1,398,808
U01 · FY2023 · DA
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$1,141,152
U01 · FY2018 · DA
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$1,020,256
UH3 · FY2022 · DA
Development of Nociceptin Receptor Agonists for Alcohol Use Disorders, Period of Performance 09/15/15 - 09/14/17; CPFF$999,993
N44 · FY2015 · HD
Development of Next-generation Pharmacotherapy for Opioid Use Disorders$869,673
UH3 · FY2024 · DA
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES$760,015
R44 · FY2016 · DA
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES$757,870
R44 · FY2014 · DA
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES$742,129
R44 · FY2015 · DA
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIES$736,013
R44 · FY2017 · DA
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$709,446
R01 · FY2014 · DA
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$703,039
R01 · FY2013 · DA
DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE$646,565
U01 · FY2020 · DA
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$646,183
R01 · FY2011 · DA
Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse Therapy$640,287
R01 · FY2010 · DA